A new wave of research is focusing on a drug that could act as an 'Ozempic for the brain,' aiming to treat a range of neurological and psychiatric conditions, including sleep disorders, attention deficit hyperactivity disorder (ADHD), and depression. The twice-daily pill, oveporexton, is designed to boost levels of orexin, a peptide produced in the hypothalamus that regulates sleep and wakefulness.
This development marks a significant advancement in the treatment of narcolepsy, a neurological condition affecting an estimated 30,000 people in the UK, often diagnosed in childhood or early adulthood. Narcolepsy is thought to arise when the immune system mistakenly attacks healthy brain cells responsible for producing orexin. Oveporexton targets type-1 narcolepsy, the most common form, by stimulating receptors on brain cells to increase orexin production. This approach addresses the root cause of the condition, unlike previous treatments that only managed symptoms.
Clinical trials involving over 270 narcolepsy patients demonstrated significant improvements in daytime alertness and an average 80% reduction in cataplexy, a sudden loss of muscle control often triggered by emotions. Side effects were generally mild, including insomnia and increased urination. The U.S. Food and Drug Administration (FDA) has already approved oveporexton for narcolepsy, and the UK's National Institute for Health and Care Excellence (NICE) is currently evaluating its cost-effectiveness for NHS treatment, with a decision anticipated by April 2027.
Beyond narcolepsy, researchers are exploring orexin-boosting medications for other conditions. Because orexin plays a role in attention, reward processing, and motivation, there is hope that these drugs could also be effective in treating ADHD and depression. Some patients in narcolepsy trials have reported improved attention, prompting further investigation into ADHD applications. Additionally, blocking an orexin receptor linked to reward and motivation is being studied as a potential treatment for addiction, while activating it could help patients with certain forms of depression.
Narcolepsy sufferers face increased health risks, including a 30% higher likelihood of premature death due to conditions exacerbated by chronic sleep disruption, such as heart disease, type 2 diabetes, and mental illness. Current treatments for narcolepsy include stimulants like modafinil, which can cause side effects such as irregular heartbeats, and sodium oxybate, a sedative that can lead to dizziness, nausea, and confusion. Oveporexton represents the first in a new class of drugs targeting narcolepsy, with other orexin receptor agonists expected in the coming years.
Professor Guy Leschziner, a neurologist specializing in sleep medicine, described a drug that stimulates orexin as the 'holy grail' of narcolepsy treatment and expressed optimism about the encouraging trial data for oveporexton. He noted that access to such a treatment would be highly beneficial for individuals with this debilitating disorder.